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We present a case of catatonia, which occurred shortly after starting a new antipsychotic, 
paliperidone, an active metabolite of risperidone. Catatonia may be caused by a variety of conditions, 
including metabolic, neurologic, psychiatric and toxic processes. Interestingly, risperidone, which 
has been thought to cause several cases of catatonia, has also been recommended as a potential 
treatment. We discuss potential mechanisms for causes of drug-induced catatonia as well as potential 
treatment options. [West J Emerg Med. 2010; 11(2):186-188.]
INTRODUCTION
Catatonia can be caused by a variety of metabolic, neurologic, 
psychiatric, and toxic conditions. Risperidone, an atypical 
antipsychotic, has been reported to induce catatonia in several 
patients,1,2 although paradoxically, antipsychotics, including 
risperidone, have been used successfully to treat catatonia.3,4 
Paliperidone, a major active metabolite of risperidone, was 
approved by the United States Food and Drug Administration 
(FDA) in December, 2006, for the treatment of schizophrenia. 
We report what we believe is the first case of catatonia 
temporally related to paliperidone, after a single dose.
CASE REPORT
An 84-year-old female with history of major depression 
and anxiety was evaluated by her psychiatrist for worsening 
anxiety and given a single dose of 3 mg of paliperidone. 
Eight hours later she became increasingly agitated and, 
according to her daughter, “looked like she was going to 
crawl out of her skin.” She then told her daughter “make 
it go away, make it go away,” and subsequently stopped 
speaking and responding to any physical or verbal stimuli, 
although she appeared awake and alert. She had no prior 
documented episodes of catatonia. Her daughter brought her 
into the local emergency department (ED).
In the ED, she had a temperature of 37.3°C, pulse 80 beats 
per minute, blood pressure 161/72 mm Hg, respiratory rate 20 
breaths per minute and oxygen saturation of 98% on room air. 
Her medications were citalopram, trazodone, levothyroxine, 
and paliperidone. She lived with her daughter, who related no 
recent trauma. The patient previously took risperidone, but it 
had been discontinued after several months because of mild 
akathisia, with both restlessness and tremor. 
Physical exam showed an alert, well appearing elderly 
female in no acute distress. Her pupils were equal round 
and reactive to light; she would not comply with extraocular 
muscle testing. She did open her mouth on request and 
stuck out her tongue midline; there was no erythema, and 
mucous membranes were moist. Cardiopulmonary exam was 
unremarkable; abdominal palpation did not cause any change 
in her facial expression and was soft without masses. While 
she complied with several requests for the cranial nerve exam 
she would not move her fingers or toes when asked, but was 
noted to turn her head in all directions and roll from side to side, 
moving all extremities equally. Her brachioradialis and achilles 
reflexes were equal and Babinski reflexes were downgoing. She 
exhibited stupor and mutism with fixed postures. 
Finger-stick glucose was 114 mg/dL. Intravenous 
diphenhydramine, 25 mg and benztropine, 0.5 mg were given 
for dystonia without any change. Noncontrast head computed 
tomography (CT) was performed due to concern for stroke 
and was unremarkable. Laboratory tests showed white blood 
cell count of 7.4 K/mm3 with 60% neutrophils, her hematocrit 
was 37.6%, and platelets were 203 K/mm3. Electrolytes and 
renal function showed sodium 135 mmol/L, potassium 3.5 
mmol/L, chloride 101 mmol/L, bicarbonate 20 mmol/L, 
calcium 9.8 mg/dL, blood urea nitrogen 12 mg/dL, and 
creatinine 1.0 mg/dL.
Due to the lack of inpatient psychiatric beds, she was 
observed in the ED for 12 hours. Psychiatric consultation had 
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of paliperidone, without other therapy, she began to talk and 
interact. More detailed neurological exam showed no focal 
deficits. Her mood and affect were appropriate. She did not 
recall the events of the previous evening but remembered her 
daughter talking, although she was unable to respond. 
 
DISCUSSION
Catatonia is a neuropsychiatric syndrome characterized 
by a combination of mental, motor, vegetative, and behavioral 
signs and symptoms.5 It has been described as a syndrome 
with prominent motor signs, with positivistic or excitatory 
symptoms, including mitgehen, in which there are excited 
movements with light stimulation, even with instructions to 
the contrary. Other signs include stupor, immobility, mutism, 
and negativism, including gegenhalten (increasing resistance 
to passive movement of the limbs), waxy flexibility, posturing, 
stereotypic movements, echolalia, and echopraxia.6 Mutism 
and stupor are generally regarded as principal signs of 
catatonia, although neither are certainly pathognomonic. 
The Diagnostic and Statistical Manual of Mental 
Disorders, DSM – IV, defines catatonia as the presence of 
at least two of the following: motoric immobility, excessive 
motor activity, extreme negativism/mutism, posturing/
stereotyped movements/prominent mannerisms or grimacing, 
and echolalia or echopraxia.6
Our patient exhibited several of these features, including 
immobility, with posturing at times, and extreme negativism, 
including mutism. While her presenting differential was 
broad, lack of fever, headache, and a normal white count 
were inconsistent with infection. A lumbar puncture was not 
obtained, but complete reversal of symptoms without other 
therapy would also argue against meningitis or encephalitis. 
Non-convulsive status epilepticus or partial complex seizures 
should also be considered, although there was no history of 
a previous seizure disorder. An electroencephalogram (EEG) 
should be obtained if clinical suspicion warrants. 
Catatonia has been associated with schizophrenia, major 
depressive disorder, as well as other medical conditions, 
including alcoholism, bi-frontal tumors, encephalitis, transient 
ischemic attack, chronic obstructive pulmonary disease, 
rheumatic heart disease, Alzheimer’s and vascular dementia, 
central diabetes insipidus, closed head injury, end stage renal 
disease, and renal tubular acidosis.8 Neuroleptic malignant 
syndrome, as well as severe extrapyramidal reactions, may 
also present initially with catatonic features, and has been 
considered by some to be a subset of catatonia.9
While no studies have specifically evaluated the 
prevalence of drug-induced catatonia, studies regarding 
general causes of catatonia suggest that 17-19% of all cases 
diagnosed as medical catatonia are actually drug-induced 
catatonia.5 Another study found that antipsychotic-induced 
catatonia accounted for 24% of all catatonic patients referred 
to the ED of a general hospital.8 
Drug-induced catatonia has mostly been reported with 
psychotropic drugs, including fluphenazine, haloperidol, 
risperidone, and clozapine, non-psychotropic drugs such as 
steroids, disulfiram, ciprofloxacin, several benzodiazepines, 
as well as drugs of abuse, including phencyclidine, cannabis, 
mescaline, LSD, cocaine and ecstasy.5 While psychiatric 
disorders may simply cause catatonia, it does appear that 
medications themselves can either cause or unmask an 
underlying predisposition to catatonia. 
The mechanism by which medications cause catatonia is 
not known. Mechanisms have been proposed based on animal 
models: 1) dopamine hypoactivity at the D2 receptor, 2) 
GABA hypoactivity at the GABAA receptor and hyperactivity 
at the GABAB receptor, 3) serotonin hyperactivity at 5-HT1A 
receptor and hypoactivity at 5-HT2A receptor, and 4) glutamate 
hypoactivity at the NMDA receptor.5
Paliperidone is the active major metabolite of risperidone. 
It was approved by the FDA in December 2006 and released 
to consumers in the United States in January 2007. Its 
therapeutic activity is believed to be a result of both central 
dopamine type 2 and serotonin type 2 receptor antagonism. 
It is also an antagonist at α1 and α2 adrenergic receptors 
and H1 histaminergic receptors. Plasma concentrations are 
estimated to peak approximately 24 hours after dosing with a 
terminal half-life of approximately 23 hours. Bioavailability 
is 28% with apparent volume of distribution of 487 L. Plasma 
protein binding of paliperidone is 74%. Unlike risperidone, 
paliperidone is not extensively metabolized by the cytochrome 
P450 enzymes and is not expected to cause clinically relevant 
pharmacokinetic drug interactions.10,11 
ED evaluation of patients who present with catatonic 
symptoms requires a comprehensive evaluation and a 
wide differential and should not be initially attributed to 
the underlying psychiatric disorder. Treatable common 
causes of catatonia should be ruled out. Further diagnostic 
and laboratory studies may include complete blood count, 
comprehensive metabolic panel, thyroid stimulating hormone, 
urinalysis, cerebral spinal fluid evaluation, CT, magnetic 
resonance imaging, EEG, and other studies as clinical history 
and physical findings dictate. 
In most cases of drug-induced catatonia, stopping the 
implicated drug and supportive care is usually sufficient. 
Benzodiazepines and electroconvulsive therapy have also 
been recommended as potential treatments.5,12 Typical 
antipsychotics such as haloperidol should be avoided, 
although a trial of atypical antipsychotics (e.g. risperidone, 
olanzapine) has been suggested for patients who do not 
respond to other measures.3,4,13,14 Caution should be taken in 
considering using paliperidone in patients who have already 
had previous adverse reaction to risperidone. Anticonvulsants, 
valproate,1 and carbamazepine2 have also been reported to be 
effective but may take longer to work than benzodiazepines. 
The Naranjo scale of adverse drug reactions15 is a 
validated score that assesses the probability of a causal 
relationship between a drug and a clinical event and is 
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reported based on several criteria as definite, probable, 
possible, and doubtful. Although this medication-catatonia 
relationship was scored as “possible” on the Naranjo scale, 
there had been no other change in medications or initiation of 
other medications, which may have been responsible for her 
condition. Also of note is no previous history of catatonic-like 
symptoms presented prior to initiation or after discontinuation 
of the paliperidone. 
SUMMARY
A number of medications have been associated with 
catatonia, including antipsychotics. Providers should consider 
multiple etiologies when evaluating a patient who presents 
with catatonia-like symptoms. Paliperidone, similar to 
risperidone, may be a cause of drug-induced catatonia. 
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